MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma

Y. Nezu, K. Hagiwara, Y. Yamamoto, T. Fujiwara, K. Matsuo, A. Yoshida, A. Kawai, T. Saito, T. Ochiya

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


Myxoid/round cell (RC) liposarcomas (MLS) were originally classified into two distinct populations based on histological differences; a myxoid component and a RC component. It is notable that, depending on an increase of the RC component, the prognosis significantly differs. Hence, the RC component is associated with metastasis and poor prognosis. However, the molecular mechanisms that contribute to the malignancy of the RC component still remain largely unknown. Here, we report microRNA-135b (miR-135b), a key regulator of the malignancy, highly expressed in the RC component and promoting MLS cell invasion in vitro and metastasis in vivo through the direct suppression of thrombospondin 2 (THBS2). Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor. The expression levels of miR-135b and THBS2 significantly correlated with a poor prognosis in MLS patients. Overall, our study reveals that the miR-135b/THBS2/MMP2 axis is tightly related to MLS pathophysiology and has an important clinical implication. This work provides noteworthy evidence for overcoming metastasis and improving patient outcomes, and sheds light on miR-135b and THBS2 as novel molecular targets for diagnosis and therapy in MLS.

Original languageEnglish
Pages (from-to)6177-6188
Number of pages12
Issue number48
Publication statusPublished - Dec 1 2016

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'MiR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma'. Together they form a unique fingerprint.

Cite this